HuMax-IL8

DRUG2 trials

Sponsors

Bristol-Myers Squibb, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Conditions

Head and Neck Squamous Cell CarcinomaSolid Tumor

Phase 1

HuMax-IL8 (Interleukin8) in Patients With Advanced Malignant Solid Tumors

CompletedNCT02536469

Bristol-Myers SquibbSolid Tumor

Start: 2015-08-31End: 2016-11-30Updated: 2017-02-03

Phase 2

Neoadjuvant Targeting of Myeloid Cell Populations in Combination With Nivolumab in Head & Neck Ca

Active, not recruitingNCT04848116

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsHead and Neck Squamous Cell Carcinoma

Start: 2021-04-24End: 2030-11-01Target: 24Updated: 2026-05-14

Related Papers

Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors

Journal for ImmunoTherapy of Cancer2019-09-05254 citations

Phase I trial of BMS-986253, an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors.

Journal of Clinical Oncology2018-05-2012 citations